MYND Life Sciences Announces Collaborative Research Agreement with University of British Columbia
MYND’s Second CRA focuses on Novel Therapies for Neurological Diseases of the Brain VANCOUVER, BC, Jan. 12, 2022 /CNW/ – MYND Life...
MYND Life Sciences Announces Collaborative Research Agreement with University of British Columbia
MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application
MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation
MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation
MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test
MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease
MYND Executes LOI to Enter into a Clinical Research Collaboration with Revitalist
MYND Life Sciences Announces Appointment of New Director
MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer&
MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Mil
MYND Life Sciences Inc. to Present at Psychedelics Virtual Investor Conference on October 13
MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – M
MYND Life Sciences Inc. Announces RSU Grant
MYND Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit Offer
MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering
MYND Life Sciences Announces DTC Eligibility
MYND Life Sciences Provides Corporate Update
This Canadian psychedelic drug company is working on a vaccine for depression
MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related fo
MYND Life Sciences Announces LOI with Eyam Vaccines and Immunotherapeutics